Gene expression signature in transplantation tolerance

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1414-1418

  Braza, Faouzi ^a,b   Soulillou, Jean Paul ^b   Brouard, Sophie ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b INSERM   (France)

Author keywords

B cells; Gene expression; Microarray; Signature; Tolerance; Transplantation

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

B LYMPHOCYTE; BIOINFORMATICS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GRAFT SURVIVAL; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON HOMEOSTASIS; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOCYTE FUNCTION; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVIEW; TRANSPLANTATION TOLERANCE;

BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSPLANTATION TOLERANCE;

EID: 84862769981     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.024     Document Type: Review

References (55)

1. Nankivell B.J., Borrows R.J., Fung C.L.-S., O'Connell P.J., Allen R.D.M., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med déc 11 2003, 349(24):2326-2333.
2. Stegall M.D., Everson G.T., Schroter G., et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology janv 1997, 25(1):173-177.
3. Soulillou J.P., Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation déc 27 2001, 72(12 Suppl.):S89-S93.
4. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med sept 4 2003, 349(10):931-940.
5. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med déc 20 2007, 357(25):2601-2614.
6. Sharabi Y., Sachs D.H. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med févr 1 1989, 169(2):493-502.
7. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med janv 24 2008, 358(4):353-361.
8. Scandling J.D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med janv 24 2008, 358(4):362-368.
9. Cosimi A.B., Burton R.C., Colvin R.B., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation déc 1981, 32(6):535-539.
10. Vincenti F., Nashan B., Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc aoÛt 1998, 30(5):2155-2158.
11. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med aoÛt 25 2005, 353(8):770-781.
12. Poirier N., Azimzadeh A.M., Zhang T., et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med févr 3 2010, 2(17):17ra10.
13. Lerut J., Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant aoÛt 2006, 6(8):1774-1780.
14. Roussey-Kesler G., Giral M., Moreau A., et al. Clinical operational tolerance after kidney transplantation. Am J Transplant avr 2006, 6(4):736-746.
15. Sánchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl nov 2011, 17(Suppl. 3):S69-S73.
16. Brouard S., Mansfield E., Braud C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A sept 25 2007, 104(39):15448-15453.
17. Martínez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest aoÛt 2008, 118(8):2845-2857.
18. Newell K.A., Asare A., Kirk A.D., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest juin 2010, 120(6):1836-1847.
19. Sagoo P., Perucha E., Sawitzki B., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest juin 2010, 120(6):1848-1861.
20. Pallier A., Hillion S., Danger R., et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int sept 2010, 78(5):503-513.
21. Lozano J.J., Pallier A., Martinez-Llordella M., et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant sept 2011, 11(9):1916-1926.
22. Canales R.D., Luo Y., Willey J.C., et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol sept 2006, 24(9):1115-1122.
23. Patel A.C. Basic science for the practicing physician: gene expression microarrays. Ann Allergy Asthma Immunol sept 2008, 101(3):325-332.
24. Brouard S., Le Bars A., Dufay A., et al. Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int juin 2011, 24(6):536-547.
25. Moraes-Vieira P.M.M., Takenaka M.C.S., Silva H.M., et al. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol févr 2012, 142(2):117-126.
26. Louis S., Braudeau C., Giral M., et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation févr 15 2006, 81(3):398-407.
27. Perez-Andres M., Paiva B., Nieto W.G., et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010, 78(Suppl. 1):S47-S60.
28. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl févr 2001, 78:S206-S211.
29. Smogorzewski M., Massry S.G. Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int Suppl févr 2001, 78:S186-S189.
30. Pahl M.V., Gollapudi S., Sepassi L., Gollapudi P., Elahimehr R., Vaziri N.D. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant janv 2010, 25(1):205-212.
31. Porcheray F., Wong W., Saidman S.L., et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant sept 2009, 9(9):2126-2135.
32. Cancro M.P. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol sept 2009, 9(9):657-661.
33. Scholz J.L., Cancro M.P. Resolve, revise, and relax: The 3 Rs of B cell repertoire adjustment. Immunol Lett mars 30 2012, 143(1):2-8.
34. Parsons R.F., Vivek K., Rostami S.Y., et al. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J Immunol janv 1 2011, 186(1):614-620.
35. Parsons R.F., Redfield R.R., Rodriguez E., et al. Primary B cell repertoire remodeling to achieve humoral transplantation tolerance. Semin Immunol avr 2012, 24(2):109-114.
36. Fan X., Ang A., Pollock-Barziv S.M., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med nov 2004, 10(11):1227-1233.
37. Le Texier L., Thebault P., Lavault A., et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant mars 2011, 11(3):429-438.
38. Blair P.A., Noreña L.Y., Flores-Borja F., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity janv 29 2010, 32(1):129-140.
39. Bouaziz J.-D., Calbo S., Maho-Vaillant M., et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol oct 2010, 40(10):2686-2691.
40. Lemoine S., Morva A., Youinou P., Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun mai 2011, 36(3-4):228-238.
41. Iwata Y., Matsushita T., Horikawa M., et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood janv 13 2011, 117(2):530-541.
42. Garaud S., Morva A., Lemoine S., et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol avr 15 2011, 186(8):4835-4844.
43. Newell K.A., Chong A.S. Making a B-line for transplantation tolerance. Am J Transplant mars 2011, 11(3):420-421.
44. Martínez-Llordella M., Puig-Pey I., Orlando G., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant févr 2007, 7(2):309-319.
45. Bohne F., Martínez-Llordella M., Lozano J.-J., et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest janv 3 2012, 122(1):368-382.
46. Tiegs G., Lohse A.W. Immune tolerance: what is unique about the liver. J Autoimmun févr 2010, 34(1):1-6.
47. Thomson A.W., Knolle P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol nov 2010, 10(11):753-766.
48. Roland C.R., Mangino M.J., Duffy B.F., Flye M.W. Lymphocyte suppression by Kupffer cells prevents portal venous tolerance induction: a study of macrophage function after intravenous gadolinium. Transplantation mai 1993, 55(5):1151-1158.
49. He F., Chen Z., Xu S., et al. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection. Surgery juin 2009, 145(6):663-674.
50. Fujimoto M., Naka T. SOCS1, a negative regulator of cytokine signals and TLR responses, in human liver diseases. Gastroenterol Res Pract 2010, 2010(pii):470468.
51. Gri G., Piconese S., Frossi B., et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity nov 14 2008, 29(5):771-781.
52. Foucher Y., Daguin P., Akl A., et al. A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int déc 2010, 78(12):1288-1294.
53. Abramowicz D., Del Carmen Rial M., Vitko S., et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol juill 2005, 16(7):2234-2240.
54. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med déc 20 2007, 357(25):2562-2575.
55. Pallardó L.M., Oppenheimer F., Guirado L., et al. Calcineurin inhibitor reduction based on maintenance immunosuppression with mycophenolate mofetil in renal transplant patients: POP study. Transplant Proc sept 2007, 39(7):2187-2189.